Christian P Pilarsky

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6208702/christian-p-pilarsky-publications-by-year.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150 papers	16,419 citations	55 h-index	127 g-index
161 ext. papers	19,238 ext. citations	8.6 avg, IF	5.76 L-index

#	Paper	IF	Citations
150	Pre-clinical Models of Metastasis in Pancreatic Cancer. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 748631	5.7	2
149	Microfluidics applications for high-throughput single cell sequencing. *Journal of Nanobiotechnology*, **2021**, 19, 312	9.4	8
148	Deep Learning Improves Pancreatic Cancer Diagnosis Using RNA-Based Variants. *Cancers*, **2021**, 13,	6.6	2
147	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. *Gastroenterology*, **2021**, 160, 362-377.e13	13.3	32
146	Identification and validation of a multivariable prediction model based on blood plasma and serum metabolomics for the distinction of chronic pancreatitis subjects from non-pancreas disease control subjects. *Gut*, **2021**, 70, 2150-2158	19.2	6
145	The role of miR-200b/c in balancing EMT and proliferation revealed by an activity reporter. *Oncogene*, **2021**, 40, 2309-2322	9.2	6
144	Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. *Cells*, **2021**, 10,	7.9	3
143	Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells. *Cancers*, **2021**, 13,	6.6	2
142	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. *Cell Reports*, **2020**, 31, 107625	10.6	34
141	MiR-132 controls pancreatic beta cell proliferation and survival through Pten/Akt/Foxo3 signaling. *Molecular Metabolism*, **2020**, 31, 150-162	8.8	23
140	Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. *Annals of Surgery*, **2020**, 272, 366-376	7.8	24
139	Intracellular Quantification and Localization of Label-Free Iron Oxide Nanoparticles by Holotomographic Microscopy. *Nanotechnology, Science and Applications*, **2020**, 13, 119-130	3.9	3
138	Microbiome Patterns in Matched Bile, Duodenal, Pancreatic Tumor Tissue, Drainage, and Stool Samples: Association with Preoperative Stenting and Postoperative Pancreatic Fistula Development. *Journal of Clinical Medicine*, **2020**, 9,	5.1	5
137	The Role of Exosomes in Pancreatic Cancer. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	29
136	Chemoresistance in Pancreatic Cancer. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	129
135	Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	31
134	Cytosolic 5Rnucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. *EBioMedicine*, **2019**, 40, 394-405	8.8	16

133	The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. *Science*, **2019**, 364, 1156-1162	33.3	92
132	Influence of Body Mass Index on Long-Term Outcome in Patients with Rectal Cancer-A Single Centre Experience. *Cancers*, **2019**, 11,	6.6	10
131	c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	57
130	8 Integrin Mediates Pancreatic Cancer Cell Radiochemoresistance. *Molecular Cancer Research*, **2019**, 17, 2126-2138	6.6	13
129	CRISPR Cas9 in Pancreatic Cancer Research. *Frontiers in Cell and Developmental Biology*, **2019**, 7, 239	5.7	4
128	Silenced ZNF154 Is Associated with Longer Survival in Resectable Pancreatic Cancer. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	3
127	Addendum: Liu, B. et al. The Effect of GPRC5a on the Proliferation, Migration Ability, Chemotherapy Resistance, and Phosphorylation of GSK-3 In Pancreatic Cancer. Int. J. Mol. Sci. 2018, 19, 1870. *International Journal of Molecular Sciences*, **2019**, 20, 1540	6.3	78
126	CRISPR/Cas9-Mediated Knock-Out of Kras Mutated Pancreatic Cancer Cell Lines. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	10
125	Cancer Is Associated with Alterations in the Three-Dimensional Organization of the Genome. *Cancers*, **2019**, 11,	6.6	9
124	Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imaging. *Proteomics - Clinical Applications*, **2019**, 13, e1800046	3.1	11
123	Identification of Prognostic Biomarkers by Combined mRNA and miRNA Expression Microarray Analysis in Pancreatic Cancer. *Translational Oncology*, **2018**, 11, 700-714	4.9	28
122	Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. *Gut*, **2018**, 67, 128-137	19.2	142
121	The Effect of GPRC5a on the Proliferation, Migration Ability, Chemotherapy Resistance, and Phosphorylation of GSK-3 In Pancreatic Cancer. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	18
120	Analysis of DNA Hypermethylation in Pancreatic Cancer Using Methylation-Specific PCR and Bisulfite Sequencing. *Methods in Molecular Biology*, **2018**, 1856, 269-282	1.4	9
119	The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. *Nature Cell Biology*, **2017**, 19, 518-529	23.4	513
118	The G Protein-Coupled Receptor RAI3 Is an Independent Prognostic Factor for Pancreatic Cancer Survival and Regulates Proliferation via STAT3 Phosphorylation. *PLoS ONE*, **2017**, 12, e0170390	3.7	18
117	Hypermutation In Pancreatic Cancer. *Gastroenterology*, **2017**, 152, 68-74.e2	13.3	130
116	Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens. *Oncotarget*, **2017**, 8, 34283-34297	3.3	3

115	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. *Cell Reports*, **2016**, 14, 907-919	10.6	75
114	Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature*, **2016**, 531, 47-52	50.4	1785
113	Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy. *Oncotarget* , **2016**, 7, 3984-92	3.3	10
112	Gene Expression Analysis in the Age of Mass Sequencing: An Introduction. *Methods in Molecular Biology*, **2016**, 1381, 67-73	1.4	2
111	Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature*, **2015**, 518, 495-501	50.4	1579
110	A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy. *Neoplasia*, **2015**, 17, 155-66	6.4	59
109	Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature*, **2015**, 523, 177-82	50.4	1678
108	A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer. *Nature Genetics*, **2015**, 47, 47-56	36.3	59
107	Overexpression of SIX1 is an independent prognostic marker in stage I-III colorectal cancer. *International Journal of Cancer*, **2015**, 137, 2104-13	7.5	25
106	Differential gene expression in human abdominal aortic aneurysm and aortic occlusive disease. *Oncotarget*, **2015**, 6, 12984-96	3.3	54
105	Analysis of DNA methylation in pancreatic cancer: an update. *Methods in Molecular Biology*, **2015**, 1238, 173-81	1.4	4
104	Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor signaling. *Cell*, **2014**, 157, 382-394	56.2	325
103	Gene Expression Profiling in Pancreatic Cancer **2014**, 151-167		
102	Imaging mass spectrometry to discriminate breast from pancreatic cancer metastasis in formalin-fixed paraffin-embedded tissues. *Proteomics*, **2014**, 14, 956-64	4.8	58
101	Genomics of pancreatic ductal adenocarcinoma. *Hepatobiliary and Pancreatic Diseases International*, **2014**, 13, 381-5	2.1	2
100	STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. *Genome Medicine*, **2014**, 6, 9	14.4	22
99	Differential gene expression in the proximal neck of human abdominal aortic aneurysm. *Atherosclerosis*, **2014**, 233, 211-8	3.1	33
98	PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. *Journal of Pathology*, **2014**, 234, 502-13	9.4	34

97	Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. *Oncotarget*, **2014**, 5, 12978-89	3.3	27
96	Microarray meta-analysis defines global angiogenesis-related gene expression signatures in human carcinomas. *Molecular Carcinogenesis*, **2013**, 52, 29-38	5	10
95	Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma. *BMC Surgery*, **2013**, 13, 12	2.3	37
94	WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. *Neoplasia*, **2013**, 15, 11-22	6.4	57
93	Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer. *Neoplasia*, **2013**, 15, 1354-62	6.4	24
92	Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. *Annals of Surgery*, **2013**, 258, 324-30	7.8	92
91	Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. *Molecular and Cellular Proteomics*, **2013**, 12, 2820-32	7.6	73
90	CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 12325-30	11.5	181
89	Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. *PLoS ONE*, **2013**, 8, e65144	3.7	44
88	Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. *Journal of Surgical Research*, **2012**, 172, 29-39	2.5	46
87	Association studies of the copy-number variable □defensin cluster on 8p23.1 in adenocarcinoma and chronic pancreatitis. *BMC Research Notes*, **2012**, 5, 629	2.3	12
86	DNA methylation in pancreatic cancer: protocols for the isolation of DNA and bisulfite modification. *Methods in Molecular Biology*, **2012**, 863, 273-80	1.4	3
85	Feedback within the inter-cellular communication and tumorigenesis in carcinomas. *PLoS ONE*, **2012**, 7, e36719	3.7	15
84	Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. *PLoS Computational Biology*, **2012**, 8, e1002511	5	120
83	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. *Nature*, **2012**, 486, 266-70	50.4	253
82	Recent patents concerning targeted therapy of apoptosis resistance in pancreatic cancer. *Recent Patents on DNA & Gene Sequences*, **2011**, 5, 28-34		4
81	Chronic pancreatitis: early results of pancreatoduodenectomy and analysis of risk factors. *Pancreas*, **2011**, 40, 925-30	2.6	14
80	Hepatocyte nuclear factor (HNF) 4□expression distinguishes ampullary cancer subtypes and prognosis after resection. *Annals of Surgery*, **2011**, 254, 302-10	7.8	18

79	RET-protooncogene variants in patients with sporadic neoplasms of the digestive tract and the central nervous system. *International Journal of Colorectal Disease*, **2011**, 26, 835-40	3	6
78	Molecular profiles and clinical outcome of stage UICC II colon cancer patients. *International Journal of Colorectal Disease*, **2011**, 26, 847-58	3	31
77	Quality of life in patients after pancreaticoduodenectomy for chronic pancreatitis. *Journal of Gastrointestinal Surgery*, **2011**, 15, 1143-50	3.3	17
76	An update on molecular research of pancreatic adenocarcinoma. *Anti-Cancer Agents in Medicinal Chemistry*, **2011**, 11, 411-7	2.2	8
75	Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. *Molecular and Cellular Proteomics*, **2011**, 10, M111.008599	7.6	89
74	Differences in CD75s- and iso-CD75s-ganglioside content and altered mRNA expression of sialyltransferases ST6GAL1 and ST3GAL6 in human hepatocellular carcinomas and nontumoral liver tissues. *Glycobiology*, **2011**, 21, 584-94	5.8	25
73	Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach?. *Cancers*, **2011**, 3, 2286-301	6.6	2
72	The role of apoptosis in the pathology of pancreatic cancer. *Cancers*, **2010**, 3, 1-16	6.6	17
71	Serum tumor markers in pancreatic cancer-recent discoveries. *Cancers*, **2010**, 2, 1107-24	6.6	38
70	Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis. *PLoS ONE*, **2010**, 5, e12243	3.7	28
69	Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. *Oncologist*, **2010**, 15, 1294-309	5.7	75
68	Molecular pathogenesis of pancreatic neuroendocrine tumors. *Cancers*, **2010**, 2, 1901-10	6.6	4
67	Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells. *Journal of Surgical Research*, **2010**, 160, 29-34	2.5	35
66	Functional analysis of LOXL2 in pancreatic carcinoma. *International Journal of Colorectal Disease*, **2010**, 25, 303-11	3	43
65	Molekularbiologie des Pankreaskarzinoms. *Onkologe*, **2010**, 16, 557-567	0.1	
64	Simultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis. *BMC Cancer*, **2010**, 10, 379	4.8	32
63	The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. *European Urology*, **2010**, 57, 398-406	10.2	34
62	PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. *Journal of Clinical Investigation*, **2010**, 120, 2516-27	15.9	80

61	Search for and identification of novel tumor-associated autoantigens. *Methods in Molecular Biology*, **2010**, 576, 213-30	1.4	2
60	Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science*, **2009**, 324, 1457-61	33.3	2364
59	MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 3918-28	5.6	194
58	An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. *Journal of Molecular Medicine*, **2009**, 87, 633-44	5.5	60
57	Detection of autoantibodies to tumour-associated antigens in sera of patients with systemic autoimmunity using a novel protein microblot array. *Scandinavian Journal of Immunology*, **2009**, 69, 563-9	3.4	6
56	Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. *Clinical Chemistry*, **2009**, 55, 1337-46	5.5	385
55	Apoptotic Signaling in Pancreatic Cancer Therapeutic Application (Supplemental Data). *Current Cancer Therapy Reviews*, **2009**, 5, 122-133	0.4	4
54	Molecular pathology of invasive lobular breast carcinoma. *Breast Disease*, **2008**, 30, 9-14	1.6	1
53	Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. *British Journal of Cancer*, **2008**, 99, 1484-92	8.7	45
52	ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. *European Urology*, **2008**, 54, 1097-106	10.2	61
51	Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. *Journal of Cellular and Molecular Medicine*, **2008**, 12, 2823-35	5.6	72
50	DNA methylation biomarkers for blood-based colorectal cancer screening. *Clinical Chemistry*, **2008**, 54, 414-23	5.5	374
49	Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. *PLoS ONE*, **2008**, 3, e3759	3.7	290
48	Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer. *Molecular Cancer Therapeutics*, **2008**, 7, 2464-75	6.1	27
47	Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer. *Journal of Nuclear Medicine*, **2008**, 49, 1362-70	8.9	37
46	Recent patents concerning diagnostic and therapeutic applications of aberrantly methylated sequences in pancreatic cancer. *Recent Patents on DNA & Gene Sequences*, **2008**, 2, 97-106		5
45	Data-aware SOA for Gene Expression Analysis Processes **2007**,		2
44	Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. *Cancer Research*, **2007**, 67, 8344-50	10.1	263

43	Genome-wide expression patterns of invasion front, inner tumor mass and surrounding normal epithelium of colorectal tumors. *Molecular Cancer*, **2007**, 6, 79	42.1	12
42	Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. *Oncogene*, **2007**, 26, 6851-62	9.2	92
41	Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. *British Journal of Cancer*, **2007**, 97, 1432-40	8.7	63
40	Tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphisms in a Caucasian population with abdominal aortic aneurysm. *World Journal of Surgery*, **2007**, 31, 2248-54	3.3	27
39	Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. *Molecular Cancer Research*, **2007**, 5, 153-63	6.6	50
38	Structural templates predict novel protein interactions and targets from pancreas tumour gene expression data. *Bioinformatics*, **2007**, 23, i115-24	7.2	16
37	Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III. *International Journal of Cancer*, **2006**, 119, 1829-36	7.5	33
36	Two-phase clustering strategy for gene expression data sets **2006**,		7
35	Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. *Clinical Cancer Research*, **2006**, 12, 6444-51	12.9	53
34	Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. *Clinical Cancer Research* , **2006**, 12, 3950-60	12.9	124
33	A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. *Molecular Cancer*, **2006**, 5, 37	42.1	45
32	High-resolution analysis of chromosomal imbalances using the Affymetrix 10K SNP genotyping chip. *Genomics*, **2005**, 85, 392-400	4.3	25
31	Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. *Pancreatology*, **2005**, 5, 370-9	3.8	46
30	Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. *Oncogene*, **2005**, 24, 5079-88	9.2	143
29	Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. *Journal of Pathology*, **2005**, 205, 359-76	9.4	144
28	Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. *Clinical Cancer Research*, **2005**, 11, 4415-29	12.9	83
27	RNA expression profiling of normal and tumor cells following photodynamic therapy with 5-aminolevulinic acid-induced protoporphyrin IX in vitro. *Molecular Cancer Therapeutics*, **2005**, 4, 516-28	6.1	34
26	Structural Protein Interactions Predict Kinase-Inhibitor Interactions in Upregulated Pancreas Tumour Genes Expression Data. *Lecture Notes in Computer Science*, **2005**, 1-11	0.9	

25	ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. *British Journal of Cancer*, **2004**, 90, 1053-8	8.7	110
24	Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. *Laboratory Investigation*, **2004**, 84, 465-78	5.9	125
23	Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. *International Journal of Colorectal Disease*, **2004**, 19, 401-13	3	21
22	CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. *Prostate*, **2004**, 58, 183-92	4.2	109
21	Prevalence of familial pancreatic cancer in Germany. *International Journal of Cancer*, **2004**, 110, 902-6	7.5	66
20	Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. *Pancreatology*, **2004**, 4, 454-60	3.8	64
19	Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. *Neoplasia*, **2004**, 6, 744-50	6.4	255
18	DNA microarray analysis of pancreatic malignancies. *Pancreatology*, **2004**, 4, 587-97	3.8	36
17	Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. *Neoplasia*, **2004**, 6, 611-22	6.4	156
16	No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma. *Cancer Letters*, **2004**, 214, 63-8	9.9	18
15	Prospective evaluation of ultrasound and colour duplex imaging for the assessment of surgical resectability of pancreatic tumours. *Langenbecks Archives of Surgery*, **2003**, 388, 392-400	3.4	5
14	Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2003**, 443, 508-17	5.1	93
13	Identification of candidate tumor-suppressor genes in 6q27 by combined deletion mapping and electronic expression profiling in lymphoid neoplasms. *Genes Chromosomes and Cancer*, **2003**, 37, 421-6	5	33
12	ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. *Prostate*, **2003**, 54, 34-43	4.2	122
11	WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. *Journal of Pathology*, **2003**, 201, 204-12	9.4	286
10	Systematic isolation of genes differentially expressed in normal and cancerous tissue of the pancreas. *Pancreatology*, **2003**, 3, 169-78	3.8	27
9	Biological and molecular characterization of a new human ampullary cancer cell line. *Anticancer Research*, **2003**, 23, 291-8	2.3	3
8	CD24 expression is a new prognostic marker in breast cancer. *Clinical Cancer Research*, **2003**, 9, 4906-13	12.9	191

7	CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. *American Journal of Pathology*, **2002**, 161, 1215-21	5.8	211
6	Differential gene expression by endothelial cells in distinct angiogenic states. *FEBS Journal*, **2000**, 267, 2820-30		100
5	Exhaustive mining of EST libraries for genes differentially expressed in normal and tumour tissues. *Nucleic Acids Research*, **1999**, 27, 4251-60	20.1	114
4	Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. *Prostate*, **1998**, 36, 85-91	4.2	70
3	Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma. *Urology*, **1996**, 47, 525-8	1.6	26
2	Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. *Journal of Cancer Research and Clinical Oncology*, **1994**, 120, 186-8	4.9	67
1	Stable expression of gp80 (TRPM-2, clusterin), a secretory protein implicated in programmed cell death, in transfected BHK-21 cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1993**, 1179, 306-10	4.9	8